Gameto
Gameto is a New York clinical-stage biotech developing iPSC-derived ovarian support cell therapies for fertility care.
- 37
- Company
- Bee Cave, TX, USUnited States
Gameto is a New York clinical-stage biotech developing iPSC-derived ovarian support cell therapies for fertility care.
gametogen.comCrawled Oct 16, 2026
Gameto appointed Dr. Ghassan (Gus) Haddad as chief medical officer.
Gameto appointed Dr. Jaime Knopman as chairwoman of its Clinical Advisory Board. The biotechnology company focuses on advancing treatment options in women’s health and reproductive longevity.
Gameto is seeking an associate to the CEO office to support leadership on strategic, financial, and operational initiatives across investor relations, business development, and scientific teams. The role calls for 1–3 years of investment banking or management consulting experience.
Gameto describes its team as collaborative and united by a mission to use scientific breakthroughs to create products.
Gameto is a biotechnology company in women’s health, co-founded by Dina Radenkovic and Martin Varsavsky.
The company is seeking a medical director of global clinical operations to manage international clinical studies focused on its IVF/IVM product Fertilo. The role is based in Spain and lists a salary range of $90,000–$120,000 plus bonuses.
The company says advances in fertility could improve the female reproductive journey and states that its mission is to transform reproductive health.
Gameto applies biotechnology to fertility treatments and menopause care.
Gameto, Inc. states that its privacy policy covers its websites and explains how the company treats personal and other information it receives or collects.
Gameto, Inc. provides its website and associated websites subject to its Terms and Conditions of Use and other written agreements.
Ferring Pharma acquires Gameto, a US women’s health startup, in a deal valued up to **$1.38 billion**. The move expands Ferring’s focus on **fertility treatments**, leveraging Gameto’s specialized expertise in reproductive health solutions. The acquisition strengthens Ferring’s portfolio in a high-growth segment of women’s healthcare.
Oct 2026pharmaphorumNews article
Ferring Pharmaceuticals and Gameto have signed a merger agreement for a proposed global acquisition. The deal aims to combine Gameto’s reproductive-health innovations with Ferring’s established expertise and global reach in reproductive medicine. The agreement marks a key step toward a potential consolidation in the sector.
Oct 2026Gameto | Redefining women's healthNews article
Gameto licenses foundational meiosis intellectual property from Harvard. The license is intended to advance the company's human ovary-in-a-dish platform.
Jan 2026GlobeNewswireNews article
GameTo, a biotech startup, investigates ovarian aging as a potential key to understanding and addressing broader aging processes. The company’s research could lead to breakthroughs in in vitro fertilization (IVF) and expand treatment options in women’s health by focusing on an understudied biological area.
Dec 2025Washington PostNews article